Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat

J Infect Dis. 2022 Mar 2;225(5):856-861. doi: 10.1093/infdis/jiab487.


We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell-associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration. NCT03803605.

Keywords: HIV latency; broadly neutralizing antibody; latency reversal.

Publication types

  • Clinical Study

MeSH terms

  • Broadly Neutralizing Antibodies
  • CD4-Positive T-Lymphocytes
  • HIV Infections*
  • HIV-1* / genetics
  • Humans
  • Viremia / drug therapy
  • Virus Latency
  • Vorinostat / therapeutic use


  • Broadly Neutralizing Antibodies
  • Vorinostat

Associated data